Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CMA1 | P23946 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809742 | 0.85 | TSHR (0.50) | MEN1KMT2ANPC1POLBRAB9A | |
| SCHEMBL23569155 | 0.71 | ALDH1A1 (0.50) | CYP3A4ALDH1A1HSD17B10TDP1MAPK1 | |
| SCHEMBL529821 | 0.71 | TAAR1 (0.62) | CYP3A4ALDH1A1CMA1TAAR1MAPT | |
| SCHEMBL1045633 | 0.70 | CYP3A4 (0.54) | CYP3A4ALDH1A1HSD17B10TDP1MAPK1 | |
| SCHEMBL126245 | 0.70 | MAPT (0.63) | CYP3A4ALDH1A1HSD17B10TDP1MAPK1 | |
| SCHEMBL11396842 | 0.70 | CYP3A4 (0.54) | CYP3A4ALDH1A1HSD17B10TDP1MAPK1 | |
| SCHEMBL20959 | 0.70 | CYP3A4 (1.00) | CYP3A4ALDH1A1HSD17B10TDP1MAPK1 | |
| SCHEMBL4398810 | 0.70 | CYP3A4 (0.54) | CYP3A4ALDH1A1HSD17B10TDP1MAPK1 | |
| SCHEMBL22162812 | 0.70 | CA12 (0.58) | CYP3A4ALDH1A1HSD17B10TDP1MEN1 | |
| SCHEMBL8163694 | 0.70 | CYP3A4 (0.54) | CYP3A4ALDH1A1HSD17B10TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118047707-A | Direct cross coupling method of sulfoxide ylide and aryl fluorosulfonate | 南京工业大学 | 2024-05-17 | — | — | CN | claimed |
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | claimed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| US-7348348-B2 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | MERCK & CO. INC. (US) | 2008-03-25 | — | — | US | claimed |
| WO-2007081755-A2 | INDOLE-BENZIMIDAZOLE AND INDAZOLE INHIBITORS OF TYROSINE PHOSPHATASES | METABASIS THERAPEUTICS, INC. (US) | 2007-07-19 | — | — | WO | claimed |
| US-20050165072-A1 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | MERCK SHARP & DOHME CORP. | 2005-07-28 | — | — | US | claimed |
| US-6569847-B1 | Inhibitors of cathepsins for treating muscular dystrophy, osteoporosis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergy, or Chagas disease | NAEJA PHARMACEUTICALS INC. (CA) | 2003-05-27 | — | — | US | claimed |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | claimed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | claimed |
| EP-1165506-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | Naeja Pharmaceutical Inc. (CA) | 2002-01-02 | — | — | EP | claimed |
| EP-1159260-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000059881-A1 | SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS | NAEJA PHARMACEUTICAL INC (CA) | 2000-10-12 | — | — | WO | claimed |
| WO-2000055124-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| WO-1999048911-A1 | MONOBACTAM ENZYME INHIBITORS | NAEJA PHARMACEUTICAL INC. (GB) | 1999-09-30 | — | — | WO | claimed |
| US-5532233-A | PLATELET ACTIVATING FACTOR ANTAGONIST | BOEHRINGER INGELHEIM KG (DE) | 1996-07-02 | — | — | US | claimed |
| EP-0254245-B1 | Hetrazepins and processes for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1994-09-28 | — | — | EP | claimed |
| EP-0368175-A1 | 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine. | BOEHRINGER INGELHEIM KG (DE) | 1990-05-16 | — | — | EP | claimed |
| EP-0329013-A2 | Renin-inhibiting amino acid derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-08-23 | — | — | EP | claimed |
| US-4001280-A | ANTIALLERGENS | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165072-A1 | Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers | KCNN1, KCNH1, KCNN2 | CYP3A4 1902/4885ALDH1A1 993/4885HSD17B10 3022/4885 |
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | CYP3A4 1171/4885ALDH1A1 3641/4885HSD17B10 2031/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | CYP3A4 991/4885ALDH1A1 1020/4885HSD17B10 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.